POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.

Missouri requires p53 protein testing on abnormal uterine tissue samples under 'Cindi's Law'

Original title: Establishes "Cindi's Law" requiring certain diagnostic tests for uterine cancer

Last action · January 8, 2026: Second Read and Referred S Insurance and Banking CommitteeSponsor: Mike Bernskoetter

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

Senate Bill 842 establishes 'Cindi's Law', requiring all medical laboratories and providers testing abnormal endometrial tissue samples from the uterine lining to include a p53 protein test for uterine cancer diagnosis and treatment.

Why it matters

Changes medical testing requirements for pathologists and healthcare providers handling uterine tissue samples, adding mandatory p53 protein evaluations to standard diagnostic procedures.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

Patients undergoing endometrial sampling

Patients will receive mandatory p53 protein testing on abnormal uterine lining samples to assist in uterine cancer diagnosis and prognosis.

Directly affected

Medical laboratories and pathologists

Laboratories and medical providers must include p53 protein tests alongside standard testing for all abnormal cytological or histological endometrial samples.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What does Cindi's Law require laboratories to do?
It requires all abnormal endometrial samples to include a for diagnosing and treating uterine cancer.
What is a p53 test?
It is a test used to detect the presence and pattern of abnormalities in the p53 protein in tissue samples, which helps indicate the invasiveness, severity, and prognosis for various cancers.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

3 actions
  1. Jan 8, 2026SenateFloor
    Second Read and Referred S Insurance and Banking Committee
  2. Jan 7, 2026SenateIntroduced
    S First Read
  3. Dec 1, 2025Senate
    Prefiled

Version history

Only one version on file - nothing to compare yet. The text on record is the 4821S.01I - Introduced version. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Connected Entities

General Assembly, Mike Bernskoetter
OrganizationGeneral Assembly“103rd General Assembly of Missouri”Map →
PersonMike Bernskoetter“Senator, District 6, sponsor of SB 842”Map →

Sources

Open source document

www.senate.mo.gov

Analysis Score

0–100
  • Significance60
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz25
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record